Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-CD19/anti-CD3/anti-CD28 trispecific antibody CC312

A trispecific T-cell engager and antibody targeting the tumor-associated antigen (TAA) CD19, the T-cell surface antigen CD3, and the T-cell specific surface glycoprotein and co-stimulatory molecule CD28, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19/anti-CD3/anti-CD28 trispecific antibody CC312 targets and binds to CD3 and CD28 on T cells and CD19 expressed on tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen overexpressed in B-cell lineage malignancies.
Synonym:anti-CD19/CD3/CD28 trispecific antibody CC312
CD19×CD3×CD28 trispecific antibody CC312
tri-specific T-cell engager CC312
TriTE CC312
Code name:CC 312
CC-312
CC312
Search NCI's Drug Dictionary